NCT07139886

A Study to Evaluate the Safety and Efficacy of DA9601 for Acute and Chronic Gastritis and to Determine the Optimal Clinical Dosage and Administration

Phase 2b Multi-center Clinical Trials to Clarify the Efficacy and Adaptation Target of DA9601 in Patients With Acute and Chronic Gastritis, and to Determine the Optimal Clinical Dosage and Administration.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 212 (actual)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, placebo-controlled, randomized, double-blinded, paralleled group clinical study to evaluate the efficacy of 2-week treatment with DA-9601 tab in patients with acute or chronic gastritis. Subject will receive DA-9601 180mg, 360mg tab or Placebo., three times a day for two weeks.

Conditions

• Acute Gastritis
• Chronic Gastritis

Interventions

Type	Name	Description
DRUG	Stillen® Tab	Oral administration 3 times per day (in-between meals and before sleep) for 2 weeks
DRUG	Stillen® Tab Placebo	Oral administration 3 times per day (in-between meals and before sleep) for 2 weeks

Timeline

• Start date: 1997-03-14
• Primary completion: 1999-07-08
• Completion: 1999-07-08
• First posted: 2025-08-24
• Last updated: 2025-08-29

Locations

1 site across 1 country: South Korea